Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases
- Collaboration provides opportunity to build on Alexion’s more than two decades of complement leadership with expansion into RNAi-based therapies using Dicerna’s GalXC™ technology - - Agreement provides Alexion with exclusive worldwide licenses as well as development and commercial rights for two...
View HTML
Toggle Summary Archemix and Dicerna to Collaborate on Conjugated Aptamer-Dicer Substrate RNAi Therapeutics View HTML
Toggle Summary Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH) Dicerna to receive up to $201 million in upfront and success-based development and commercialization milestones, excluding royalties, for an...
View HTML
Toggle Summary Dicerna Announces Addition to NASDAQ Biotechnology Index
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. ( NASDAQ : DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective upon market open on December...
View HTML
Toggle Summary Dicerna Announces Additional Patent Claims Allowed, Broadening Coverage of Extended Dicer Substrate Therapeutic Structures View HTML
Toggle Summary Dicerna Announces Allowance of Patent Claims Covering Extended Dicer Substrate Therapeutic Structures View HTML
Toggle Summary Dicerna Announces Appointment of Biotech Industry Leader Bruce Peacock to its Board of Directors and Audit Committee
WATERTOWN, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, announced today the appointment of Bruce Peacock to its board of directors and audit committee. Mr. Peacock currently serves as chief financial and business...
View HTML
Toggle Summary Dicerna Announces Appointment of John "Jack" Green as Chief Financial Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of John B. "Jack" Green as chief financial officer (CFO), effective immediately. Mr....
View HTML
Toggle Summary Dicerna Announces Appointment of Ralf Rosskamp, M.D., as Chief Medical Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of industry veteran Ralf Rosskamp , M.D., as chief medical officer, effective June 15, 2017 ....
View HTML
Toggle Summary Dicerna Announces Closing of $70 Million Convertible Preferred Stock Financing
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company"), a leading developer of investigational ribonucleic acid interference ("RNAi") therapeutics, today announced that it has closed its previously announced stock purchase transaction for the sale of...
View HTML